| answer text |
<p>Between 1 January 2020 and 14 October 2022, members of the Voluntary Scheme for
Branded Medicines Pricing and Access have received approval for an increase to the
National Health Service list price for 35 medicines, for 120 presentations. The majority
of price increases have been concentrated in specific market segments particularly
impacted by global cost increases in the active pharmaceutical ingredient.</p><p>Price
increase requests are assessed in line with Scheme’s rules, which ensure companies
cannot make excess profits by setting a return on sales target of 6% for standard
price increase requests.</p>
|
 |
